Drug ID: 1d00000051
Drug Name: Aliskiren
Generic Names: Rasilez (300 mg) | Rasilez | Tekturna
Category: Anti- Hypertensives
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The usual recommended starting dose is 150 mg once daily. Maximum: 300mg.
Recommended In: This medication is a renin inhibitor, prescribed for hypertension. This medication decreases the substances that lead to increased blood pressure. It works by decreasing substances in the body that narrow blood vessels and raise blood pressure.
Directions For Use: It comes as a tablet to take by mouth, with or without food.
Storage: Store it at controlled room temperature (25°C).
Dosage Forms: Tablet
Side Effects: Gastrointestinal- Diarrhea and indigestion.
Central Nervous System- Headache, dizziness, fatigue and epilepsy.
Metabolic- Increased level of liver enzymes, Blood Urea Nitrogen and anemia.
In Case of Overdose: Limited data are available related to overdosage in humans. The most likely manifestation of overdosage would be hypotension. If symptomatic hypotension occurs, supportive treatment should be initiated.
Aliskiren is poorly dialyzed. Therefore, hemodialysis is not adequate to treat aliskiren overexposure.
Avoid If: Caution should be exercised in patients with history of gout, heart problems, kidney problems, kidney dialysis, diabetes, stroke, heart attack or kidney transplant, dehydration, low blood volume, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.
It may cause dizziness, lightheadedness or fainting, do not drive a car or operate machinery, get up slowly from bed while taking this medication.
It may cause dehydration, excessive sweating, vomiting or diarrhea, which leads to low blood pressure and severe allergic reactions; if it is so consult with your doctor.
Contraindicated in patients with angioedema, pregnancy, who are taking cyclosporine and hypersensitivity.
Do not use aliskiren with angiotensin receptor blockers (ARBs) and the angiotensin converting enzyme inhibitors (ACEIs)in patients with diabetes.
Monitor blood pressure, blood electrolyte levels and kidney function regularly while taking this medication.
Avoid excess dosage.
Drug Interaction: Cyclosporine
Avoid co-administration of cyclosporine with aliskiren.
Avoid co-administration of itraconazole with aliskiren.
Non-Steroidal Anti-Inflammatory Agents (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors)
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors with agents that affect the renin-angiotensinaldosterone system, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.
Dual Blockade of the renin-angiotensin-aldosterone system
The concomitant use of aliskiren with other agents acting on the renin-angiotensin-aldosterone system such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Monitor blood pressure, renal function, and electrolytes in patients on aliskiren and other agents that affect the renin-angiotensinaldosterone system.
Oral co-administration of aliskiren and furosemide reduced exposure to furosemide. Monitor diuretic effects when furosemide is co-administered with aliskiren.